STOCK TITAN

Castle Biosciences, Inc. - CSTL STOCK NEWS

Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.

Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.

Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.

The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.

Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.

The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.

For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.

Rhea-AI Summary

Castle Biosciences, Inc. (Nasdaq: CSTL) kicks off Skin Cancer Awareness Month by supporting various initiatives. The company collaborates with IMPACT Melanoma to honor the City of Friendswood's designation as a Sun Safe Leadership Model City. The Sun Safe Leadership initiative includes programs like free sunscreen dispensers, portable shade tents, prevention education, and protective clothing for outdoor workers. Castle Biosciences partners with various organizations to raise awareness, support fundraising events, and provide education during Skin Cancer Awareness Month.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.41%
Tags
none
-
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) will release its first-quarter financial results on May 2, 2024. A conference call and webcast will be held to discuss the results. Investors can access the webcast via the company's website or phone. International dial-in numbers are also available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
-
Rhea-AI Summary
Castle Biosciences, Inc. (Nasdaq: CSTL) supports Esophageal Cancer Awareness Month by collaborating with key programs and initiatives to advance research, prevention, and education. The Company partners with Esophageal Cancer Action Network, Gastro Broadcast podcast, and EndoscopyNow to promote awareness and provide holistic support for patients and the GI professional community. Castle's prognostic risk-stratification test, TissueCypher®, aims to predict progression to high-grade dysplasia or esophageal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
none
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) announces its CFO, Frank Stokes, being selected as a Top 25 CFO of Houston for the second consecutive year. Stokes is recognized for his financial leadership and contribution to the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
none
-
Rhea-AI Summary
Castle Biosciences, Inc. presents new data at EADO Congress showing DecisionDx-Melanoma and DecisionDx-SCC tests improve clinical decision-making and reduce costs. The tests accurately stratify patients with melanoma and squamous cell carcinoma, guiding treatment plans and reducing unnecessary procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) is set to present at the 23rd Annual Needham Virtual Healthcare Conference, offering a company overview on April 9, 2024. The presentation will be available via live audio webcast on the company's website, with a replay option post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) appoints Rodney Cotton to its board of directors, bringing extensive leadership experience from Roche Diagnostics. Mara G. Aspinall will not stand for re-election. Cotton's background includes financial turnarounds, global healthcare leadership, and COVID-19 response initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.09%
Tags
management
-
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) receives the Top Workplaces USA award for the third year in a row, ranking 28th among 370 companies. The company is recognized for its exceptional workplace culture that prioritizes employee empowerment, trust, transparency, and authenticity. The award is attributed to the dedication of Castle's employees and their commitment to improving health through innovative tests that guide patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
-
Rhea-AI Summary
Castle Biosciences presents new data at SSO 2024 demonstrating DecisionDx-Melanoma's ability to predict risk of sentinel lymph node positivity in patients with cutaneous melanoma. The test can help identify high-risk patients who may benefit from more intensive treatment pathways, such as sentinel lymph node biopsy and imaging surveillance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
none
Rhea-AI Summary
Castle Biosciences, Inc. (CSTL) releases expert consensus guidelines on the use of DecisionDx-SCC test in determining adjuvant radiation therapy for high-risk squamous cell carcinoma patients. The guidelines aim to improve precision in treatment recommendations based on risk assessment and AJCC8 staging.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
none

FAQ

What is the current stock price of Castle Biosciences (CSTL)?

The current stock price of Castle Biosciences (CSTL) is $25.46 as of January 14, 2025.

What is the market cap of Castle Biosciences (CSTL)?

The market cap of Castle Biosciences (CSTL) is approximately 697.1M.

What does Castle Biosciences specialize in?

Castle Biosciences specializes in diagnostic tests for various cancers, providing genomic information to aid in treatment decisions.

When was Castle Biosciences founded?

Castle Biosciences was founded in 2008.

What types of cancer does Castle Biosciences have tests for?

Castle Biosciences has tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma.

What are some of Castle Biosciences' notable products?

Notable products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME.

Is Castle Biosciences involved in research for new diagnostic tests?

Yes, they have active research programs in rectal cancer and soft tissue sarcoma, among others.

Where can I find more information about Castle Biosciences and its products?

You can visit their official website at www.castlebiosciences.com for more detailed information.

What is the primary mission of Castle Biosciences?

The primary mission is to provide personalized, clinically actionable genomic information to make more accurate treatment decisions.

Does Castle Biosciences collaborate with other entities?

Yes, they work closely with outstanding members of the oncology community throughout the discovery, development, and utilization of their tests.

What is Castle Biosciences' financial condition?

The company is in a robust financial condition, reflecting successful commercialization efforts and consistent revenue growth.

How does Castle Biosciences contribute to cancer care?

By providing objective and accurate diagnostic tests, Castle Biosciences helps advance cancer care and improve patient outcomes.
Castle Biosciences, Inc.

Nasdaq:CSTL

CSTL Rankings

CSTL Stock Data

697.10M
27.07M
3.38%
94.29%
6%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
FRIENDSWOOD